Imugene Limited (ASX: IMU), a clinical stage immunooncology company, is set to feature its B cell immunotherapy HER-Vaxx and oncolytic virotherapy CHECKVacc at the esteemed ESMO Congress in Madrid from 20-24 October 2023. The ESMO Congress plays a significant worldwide role, providing a prominent platform for clinicians, researchers, patient advocates, journalists, and representatives from the healthcare industry to come together. Imugene's innovative research will be showcased in two poster sessions.
The first presentation (#4720) will focus on HER-Vaxx's Phase 2 study, demonstrating its potential in treating HER2+ advanced stomach cancer by generating dose-dependent anti-cancer antibodies that correlate with improved clinical outcomes. This study will be presented by Dr. Joshua Tobias, affiliated with the Medical University of Vienna. The second presentation (#4581) will feature the use of CF33-hNIS-antiPD-L1 to create an inflammatory tumor microenvironment in patients with metastatic triple-negative breast cancer, presented by Dr. Jamie Rand from the City of Hope.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
